v3.26.1
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Revenue $ 4,329 $ 3,978 $ 7,991 $ 7,959
Cost of revenue (4,150) (3,922) (7,798) (7,762)
Gross profit 179 56 193 197
G&A (41) (52) (103) (88)
Gain on sale of CFHI 0 0 124 0
Foreign currency gain (loss) (3) (30) 12 (44)
Operating profit (loss) 135 (26) 226 65
Interest expense (11) (9) (21) (21)
Interest income 32 26 57 55
Earnings (loss) before taxes 156 (9) 262 99
Income tax expense [1] (25) (765) (17) (712)
Net earnings (loss) before equity method earnings 131 (774) 245 (613)
Equity method earnings (loss) (8) 3,212 44 2,819
Net earnings 123 2,438 289 2,206
Less: Net earnings (loss) attributable to NCI 9 (22) 15 (13)
Net earnings attributable to Fluor $ 114 $ 2,460 $ 274 $ 2,219
Earnings Per Share        
Basic EPS (in dollars per share) $ 0.82 $ 14.93 $ 1.92 $ 13.30
Diluted EPS (in dollars per share) $ 0.81 $ 14.81 $ 1.89 $ 13.19
[1] Income tax expense includes tax benefits attributable to equity method earnings of $18 million in the 2026 Period. There was no tax benefit or expense attributable to equity method earnings in the 2026 Quarter. Income tax expense included tax expense attributable to equity method earnings of $757 million and $684 million in the 2025 Quarter and 2025 Period, respectively.